摘要
目的探讨Cyclin D1和claudin7在常见肾上皮性肿瘤中的表达及鉴别诊断中的价值。方法采用组织芯片技术联合免疫组化染色检测Cyclin D1和claudin7蛋白在309例常见肾上皮性肿瘤及20例正常肾组织中的表达,比较分析两种抗体对肾肿瘤诊断及鉴别诊断的价值。结果 Cyclin D1在肾嗜酸细胞瘤(renal oncocytoma,RO)、嫌色细胞癌(chromophobe renal cell carcinoma,ChRCC)、透明细胞肾细胞癌(clear cell renal cell carcinoma,CCRCC)、乳头状肾癌(papillary renal cell carcinoma,PRCC)、Xp11.2易位/TFE3基因融合相关性肾癌和透明细胞管状乳头状肾癌(clear cell tubulopapillary renal cell carcinoma,CCTPRCC)中的阳性率分别为86.2%(50/58)、8.2%(4/49)、70.0%(98/140)、8.8%(3/34)、42.9%(6/14)和71.4%(10/14)。RO分别与ChRCC、PRCC相比(χ~2=64.72、52.56,P<0.000 1),CCRCC与ChRCC(χ~2=55.87,P<0.000 1),PRCC与Xp11.2易位性肾细胞癌(χ~2=4.28,P=0.039),CCTPRCC与ChRCC(χ~2=21.69,P<0.000 1)各组间比较,差异均具有统计学意义。claudin7在RO、ChRCC、CCRCC、PRCC、Xp11.2易位/TFE3基因融合相关性肾癌和CCTPRCC中的阳性率分别为20.7%(12/58)、87.8%(43/49)、8.6%(12/140)、50%(17/34)、14.3%(2/14)、57.1%(8/14)。RO与ChRCC(χ~2=47.82,P<0.000 1)、CCRCC与CCTPRCC(χ~2=26.57,P<0.000 1)、PRCC与Xp11.2易位/TFE3基因融合相关性肾癌(χ~2=5.29,P<0.05),各组间相比差异均有统计学意义。Cyclin D1阳性/claudin7阴性对于RO的敏感性和特异性分别为69.0%和95.9%,而Cyclin D1阴性/claudin7阳性对ChRCC诊断的敏感性和特异性分别为83.7%和96.6%。Cyclin D1阳性/claudin7阴性对CCRCC的敏感性和特异性分别为65.7%和71.4%,而Cyclin D1阳性/claudin7阳性对CCTPRCC的敏感性和特异性分别为42.9%和95.0%。结论 Cyclin D1和claudin7在不同组织类型肾肿瘤中的表达有差异,联合检测对RO与ChRCC、CCRCC与ChRCC、PRCC与Xp11.2易位性肾细胞癌的鉴别诊断具有重要作用。
Purpose To investigate the value of Cyclin D1 and claudin 7 expression in the differential diagnosis of renal ep- ithelial tumors. Methods The expression of Cyclin D1 and claudin7 was detected by immunohistochemical staining with tis-sue mieroarray. Totally 309 cases of renal epithelial tumors and 20 cases of normal renal tissues were collected for immunohisto- chemical staining. Comparative analysis for the values of Cyclin DIand claudin 7 was performed on the diagnosis and differential di- agnosis of renal tumors. Results The positive rates of Cyclin D1 in renal oncocytoma （RO）, chromophobe renal cell carcinoma （ChRCC）, clear cell renal cell carcinoma （CCRCC） , papillary renal cell carcinoma （PRCC） , Xpl 1.2 translocation/TFE3 gene fusion associated renal cell carcinoma （ Xpl 1.2/TFE3 ） and clear cell tubulopapillary renal cell carcinoma （CCTPRCC） were 86.2% （50/58）, 8.2% （4/49）, 70.0% （98/140）, 8.8% （3/34）, 42. 9% （6/14）, and 71.4% （10/14）, respectively. The positive rates of RO were significantly different from those of ChRCC and PRCC （χ2 = 64. 72, 52. 56, P 〈 0. 000 1 ）. Signifi- cant differences in positive rates of CCRCC and ChRCC （ χ2 = 55. 87, P 〈 0. 000 1 ）, PRCC and Xpl 1.2/TFE3 （ χ2 = 4. 28, P =0. 039）, CCTPRCC and ChRCC （χ2 =21.69, P 〈0. 000 1 ） were also observed. The positive rates of claudin 7 in RO, ChRCC, CCRCC, PRCC, Xpll. 2/TFE3 and CCTPRCC were 20.7% （12/58）, 87.8% （43/49）, 8.6% （12/140）, 50% （17/34）, 14. 3% （2/14）, and 57.1% （8/14）, respectively.There were significant differences in positive ratios of RO and ChRCC （χ2 =47.82, P〈0.000 1）, CCRCC and CCTPRCC （χ2 = 26. 57, P 〈 0. 000 1 ）, PRCC and Xpl 1.2/TFE3 （ χ2 = 5. 29, P 〈 0. 05 ）. The sensitivity and specificity of Cyclin D1 ＋/claudin 7- immunophenotype for RO were 69% and 95.9% respectively. The diagnostic sensitivity and specificity of Cyclin D1 -/claudin 7 ＋ for ChRCC were 83.7% and 96. 6%. In the identification of
出处
《临床与实验病理学杂志》
CSCD
北大核心
2017年第12期1346-1350,1355,共6页
Chinese Journal of Clinical and Experimental Pathology
基金
青岛市市南区科技局课题(2016-3-035-YY)
青岛市医药科研指导计划项目(2014WJZD195)
